 |
|
|
| |
Bone and renal safety week 48 subgroup analysis of EMERALD:
A Phase 3, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults - 2/slides
|
| |
| |
Reported by Jules Levin
16th European AIDS Conference, October 25-27, 2017. Milan
J.R. Arribas,1 C. Orkin,2 J-M. Molina,3 J Eron,4 E Van Landuyt,5 E Lathouwers,5 V Hufkens,5 R Petrovic,5 M Opsomer,5 on behalf of the EMERALD study group
1Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; 2Barts Health NHS Trust, London, UK; 3Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 4The University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
|
|
|
|
|
